Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Partial clinical hold on phase III Oncophage trials

Sep. 5, 2003

New phase I/II trial to evaluate Xcellerated T Cells in treatment of CLL

Sep. 2, 2003

Health Canada accepts Bexxar under priority review

Aug. 28, 2003

Development of AS-1403 discontinued following phase I biodistribution results

Aug. 27, 2003

German permits for 1D09C3 pave way for E.U. clinical trials

Aug. 26, 2003

Intravesical rhIL-12 in recurrent STCC of the bladder

Aug. 20, 2003

SGN-35 selectively targets CD30-positive malignancies in models of Hodgkin's disease

Aug. 13, 2003

Scancell and Celltech collaborate on antibody therapeutics to Lewis(y/b)

Aug. 11, 2003

GPC Biotech makes progress on various fronts with 1D09C3

Aug. 6, 2003

Grant supports development of cancer vaccines at Epimmune using analogue epitopes

Aug. 1, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...